Вторая линия противоопухолевой терапии метастатического колоректального рака: стратегия лечения
Аннотация
Колоректальный рак занимает одну из лидирующих позиций в мире в структуре онкологической заболеваемости. За последние десятилетия достигнуты значительные успехи в лечении метастатического колоректального рака. Однако расширение спектра эффективных противоопухолевых препаратов формирует и ряд сложностей при выборе оптимальных схем лекарственной терапии у больных с метастазами колоректального рака. В статье изложены современные аспекты II линии лечения метастатического колоректального рака, рекомендации по выбору режимов химиотерапии и назначению таргет-ных препаратов.
Об авторах
К. А. Воронцова
Российский онкологический научный центр им. Н.Н. Блохина, Москва
Россия
Россия
Н. В. Доброва
Российский онкологический научный центр им. Н.Н. Блохина, Москва
Россия
Россия
Г. В. Вышинская
Российский онкологический научный центр им. Н.Н. Блохина, Москва
Россия
Россия
Список литературы
1. FerLay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer.
2. Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. Состояние онкологической помощи населению России в 2013 году. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2014. илл. 235 с.
3. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Concensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann of Oncology, 23: 2479-2516, 2012.
4. Tournigand C, Louvet C, Ouinaux E et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. Journal of Clinical Oncology, 22(2), 2004: 229-237.
5. Seymour MT, Maughan TS, Ledermann JA et al.; FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet, 2007, 370(9582): 143-52.
6. Pitot HC, Rowland KM, Sargent DJ et al. N9841: A randomized phase III equivalence trial of iri-notecan (CPT-11) versus oxaliplatin/5-fluoro-uracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU. J Clin Oncol (MeetingAbstracts), 2005, 23(16): 3506.
7. George P Kim, Daniel J Sargent, Michelle R. Mahoney et al. Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841. JCO, 2009, 27(17): 2848-2854.
8. Rothenberg ML, Cox JV, Butts C et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/ folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Annals of Oncology, 2008, 19: 1720-1726.
9. Manzano JL, Diaz N, Rolfo C et al. Phase II comparative study of capecitabine combined with oxaliplatin (XELOX) and CPT-11 (XELIRI) for advanced colorectal cancer patients (p) previously treated with 5-FU-based chemotherapy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol. 25, No 18S (June 20 Supplement), 2007: 14544.
10. Grothey A, Jordan K, Kellner O et al. Capecitabine/ irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study. J Clin Oncol (Meeting Abstracts), 2004, 22(14): 3534.
11. Giantonio B, Catalano P, Meropol N et al. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007, 20: 1539-1544.
12. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevaci-zumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol., 2003, 21: 60.
13. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004. 350: 2335.
14. Saltz L, Clarke S, Diaz Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX 1/ NO16966, a randomized phase III trial in first line metastatic colorectal cancer. J. Clin. Oncol., 2007, 25: 4028.
15. Saltz LB, Clarke S, Diaz Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX 1/ NO16966, a randomized phase III trial in the first line treatment of metastatic colorectal cancer (MCRC). 2007, GI. Cancers. Symposium, 238.
16. Tebbutt N, Gebski V, Wilson K et al. International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial. Europ. J. Cancer., 2009, 321(7(2)): 6001.
17. Bennouna Jaffar, Sastre Javier, Dirk Arnold et al., on behalf of the ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The LANCET Oncology, 2013, 14(1): 29-37.
18. Osterlund P, Alonso-Orduna V, Schlichting C et al. Bevacizumab plus chemotherapy beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with first-line bevacizumab plus chemotherapy (ML18147): Efficacy and safety analyses by oxaliplatin vs irinotecan-based CT. Ann Oncol, 2012, 23(9): ix195.
19. Masi G, Salvatore L, Boni L et al.; on behalf of the BEBYP Study Investigators. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol., 2015, 18, pii: mdv012.
20. Masi G, Loupakis F, Salvatore L et al. A randomized study evaluating the continuation of bevacizumab beyond progression in metastatic colorectal cancer patients who received beva-cizumab as a part of first-line treatment: results of the BEBYP trial by the gruppo onco-logico nord Ovest (GONO). Ann Oncol, 2012: 23 (Suppl 9): Abstract LBA17.
21. Tzu-Fei Wang and Albert Craig Lockhart. Aflibercept in the Treatment of Metastatic Colorectal Cancer. Clin Med Insights Oncol., 2012, 6: 19-30.
22. Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17): 11393-8. Epub 2002 Aug 12.
23. Kim ES, Serur A, Huang J et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A., 2002, 20; 99(17): 11399-404. Epub 2002 Aug 12.
24. Patricia A Tang, Steven J Cohen, Christian Kollmannsberger et al. Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clin Cancer Res, November 1, 201218; 6023.
25. Van Cutsem E, Tabernero J, Lakomy R. Intravenous aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational Phase III trial (EFC10262-VELOUR).Ann Oncol., 2011, 22.
Для цитирования:
Воронцова К.А., Доброва Н.В., Вышинская Г.В. Вторая линия противоопухолевой терапии метастатического колоректального рака: стратегия лечения. Медицинский Совет. 2015;(8):55-59. https://doi.org/10.21518/2079-701X-2015-8-55-59
For citation:
Vorontsova K.A., Dobrova N.V., Vyshinskaya G.V. Second line anti-cancer therapy for metastatic colorectal cancer: treatment strategy. Meditsinskiy sovet = Medical Council. 2015;(8):55-59. (In Russ.) https://doi.org/10.21518/2079-701X-2015-8-55-59
Просмотров: 130
Послать статью по эл. почте 